Issue 33, 2017

A Perspective – can copper complexes be developed as a novel class of therapeutics?

Abstract

Although copper–ligand complexes appear to be promising as a new class of therapeutics, other than the family of copper(II) coordination compounds referred to as casiopeínas these compounds have yet to reach the clinic for human use. The pharmaceutical challenges associated with developing copper-based therapeutics will be presented in this article along with a discussion of the potential for high-throughput chemistry, computer-aided drug design, and nanotechnology to address the development of this important class of drug candidates.

Graphical abstract: A Perspective – can copper complexes be developed as a novel class of therapeutics?

Article information

Article type
Perspective
Submitted
29 May 2017
Accepted
04 Jul 2017
First published
04 Jul 2017

Dalton Trans., 2017,46, 10758-10773

A Perspective – can copper complexes be developed as a novel class of therapeutics?

M. Wehbe, A. W. Y. Leung, M. J. Abrams, C. Orvig and M. B. Bally, Dalton Trans., 2017, 46, 10758 DOI: 10.1039/C7DT01955F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements